Testing the Efficacy of Intranasal Oxytocin for the Prevention of Postpartum Depression and PTSD

Trial Profile

Testing the Efficacy of Intranasal Oxytocin for the Prevention of Postpartum Depression and PTSD

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Post-traumatic stress disorders; Postnatal depression
  • Focus Therapeutic Use
  • Acronyms IN-OXT
  • Most Recent Events

    • 07 Nov 2017 Planned number of patients changed from 20 to 90.
    • 07 Nov 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2019.
    • 07 Nov 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top